Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis

Clinical Chemistry

Volumn 54, Issue 2, 2008, Pages 388-395

  Coste, Thierry Charles ^a   Deumer, Gladys ^a   Reychler, Gregory ^a   Lebecque, Patrick ^a   Wallemacq, Pierre ^a,b   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UCB Braine l'Alleud   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID ESTER; ICOSATRIENOIC ACID; LINOLEIC ACID; POLYUNSATURATED FATTY ACID;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ERYTHROCYTE MEMBRANE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PANCREAS INSUFFICIENCY; SEX DIFFERENCE; TRANSESTERIFICATION;

8,11,14-EICOSATRIENOIC ACID; ADOLESCENT; ARACHIDONIC ACID; CYSTIC FIBROSIS; DOCOSAHEXAENOIC ACIDS; ERYTHROCYTE MEMBRANE; EXOCRINE PANCREATIC INSUFFICIENCY; FATTY ACIDS, UNSATURATED; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; PLASMA; SEX FACTORS;

EID: 39749133582     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.094623     Document Type: Article

References (40)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (Wash DC) 1989;245:1073-80.
2. Foskett JK. ClC and CFTR chloride channel gating. Annu Rev Physiol 1998;60:689-717.
3. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-86.
4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51.
5. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002;1:51-75.
6. Carroccio A, Pardo F, Montaldo G, Iapichino L, Soresi M, Averna MR, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992;37:1441-6.
7. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000;67:117-33.
8. Coste TC, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007;40:511-20.
9. Rosenlund ML, Kim HK, Kritchevsky D. Essential fatty acids in cystic fibrosis. Nature (Lond) 1974;251:719.
10. Rivers JP, Hassam AG. Defective essential-fatty-acid metabolism in cystic fibrosis. Lancet 1975;306:642-3.
11. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice. Proc Natl Acad Sci U S A 1999;96:13995-4000.
12. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9.
13. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001;138:650-5.
14. Rosentein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-95.
15. Meyts I, Wuyts W, Proesmans M, De Boeck K. Variability of fecal pancreatic elastase measurements in cystic fibrosis. J Cyst Fibros 2002;1:265-8.
16. Kalnins D, Durie PR, Pencharz P. Nutritional management of cystic fibrosis patients. Curr Opin Clin Nutr Metab Care 2007;10:348-54.
17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34.
18. Cole TJ, Feeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
19. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-20.
20. Masood A, Stark KD, Salem N Jr. A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies. J Lipid Res 2005;46:2299-305.
21. Thompson GN. Relationship between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Eur J Pediatr 1989;30:327-9.
22. Lepage G, Levy E, Ronco N, Smith L, Galeano N, Roy CC. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J Lipid Res 1989;30:1483-90.
23. Underwood BA, Denning CR, Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis. Ann N Y Acad Sci 1972;203:237-47.
24. Chase HP, Dupont J. Abnormal levels of prostaglandins and fatty acids in blood of children with cystic fibrosis. Lancet 1978;312:236-8.
25. Farrell PM, Mischler EH, Engle MJ, Brown J, Lau SM. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985;19:104-9.
26. Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzymes. Am J Clin Nutr 1998;67:912-8.
27. Thewke D, Kramer M, Sinensky MS. Transcriptional homeostatic control of membrane lipid composition. Biochem Biophys Res Commun 2000;273:1-4.
28. Aguilar PS, de Mendoza D. Control of fatty acid desaturation: a mechanism conserved from bacteria to humans. Mol Microbiol 2006;62:1507-14.
29. Poppitt SD, Kilmartin P, Butler P, Keogh GF. Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis 2005;4:30.
30. Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 2006;52:2265-72.
31. Farrell PM, Bieri JG, Fratantoni JF, Wood RE, di Sant'Agnese PA. The occurrence and effects of human vitamin E deficiency: a study in patients with cystic fibrosis. J Clin Invest 1977;60:233-41.
32. Hubbard VS, Dunn GD. Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis. Clin Chim Acta 1980;102:115-8.
33. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr 2003;27:52-7.
34. Biggemann B, Laryea MD, Schuster A, Griese M, Reinhardt D, Bremer HJ. Status of plasma and erythrocyte fatty acids and vitamin A and E in young children with cystic fibrosis. Scand J Gastroenterol 1988;23:135-41.
35. Innis SM, Davidson GF, Chen A, Dyer R, Melnyk S, James SJ. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr 2003;143:351-6.
36. Strandvik B, Svensson E, Seyberth HW. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 1996;55:419-25.
37. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006;1:420-39.
38. Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004;39:1125-32.
39. Rogiers V, Dab I, Crokaert R, Vis HL. Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. Pediatr Res 1980;14:1088-91.
40. Batal I, Ericsoussi MB, Cluette-Brown JE, O'Sullivan BP, Freedman SD, Savaille JE, Laposata M. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin Chem 2007;53:78-84.